3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharangeal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lung Neoplasms
1
Kidney Neoplasms
1
Kidney Diseases
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
CRC
1
Interventions
Magnetic Resonance Spectroscopy
8
Specimen Handling
5
Nivolumab
5
selpercatinib
4
Iodine-124
4
Biopsy
4
pembrolizumab
3
binimetinib
3
Iodine-131
3
Cetuximab
3
ulixertinib
2
trametinib
2
omipalisib
2
lenvatinib
2
larotrectinib
2
durvalumab
2
defactinib
2
dabrafenib
2
Surveys and Questionnaires
2
Sunitinib
2
Radiosurgery
2
Ipilimumab
2
Immunoglobulin G
2
Gemcitabine
2
Disulfides
2
Cyclophosphamide
2
CTLA-4 Antigen
2
tremelimumab
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
spartalizumab
×
90 days
×
Clear all
No trials found.